Rohit Gosain, MD

Medical oncologists provide comprehensive insights on the standard-of-care treatment practices for patients with advanced/metastatic HR+ breast cancer.

The Oncology Brothers and Virginia Kaklamani, MD, outline the treatment algorithm for patients with locally advanced HR+ breast cancer.

Virginia Kaklamani, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss treatment paradigms for patients with early-stage HR+ breast cancer, highlighting the differences in treatment for premenopausal and postmenopausal patients.

Harold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.

Medical oncologists discuss the various treatment options for patients with metastatic HER2+ breast cancer and where they fit into the treatment algorithm.

The Oncology Brothers and Harold J. Burstein, MD, PhD, discuss clinical approaches to treating patients with locally advanced HER2+ breast cancer.

Harold J. Burstein, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on treatment practices for patients with early-stage HER2+ breast cancer.

A panel of medical oncologists provides insights on managing toxicities in patients with triple-negative breast cancer who are receiving antibody-drug conjugates.

Ruth M. O’Regan, MD, and Anna Weiss, MD, discuss treatment paradigms for patients with metastatic triple-negative breast cancer and the role of surgery.

The expert panel provides clinical insights on treating patients with high-risk or locally advanced triple-negative breast cancer.

Ruth M. O'Regan, MD, and Anna Weiss, MD, join the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment of early-stage node-negative triple-negative breast cancer (TNBC).

Toni Choueiri, MD, and Rohit Gosain, MD summarize the implications of the CheckMate 9ER 3-year follow-up data and highlight remaining questions and unmet needs in the RCC landscape.

A brief overview of post-hoc data from the CheckMate 9ER trial examining baseline characteristics and time to subsequent therapy in patients who received at least two years of nivolumab treatment, followed by study conclusions.

Panelists continue to discuss long-term follow-up data from the CheckMate 9ER trial, focusing on treatment-related adverse events seen in patients with ccRCC treated with nivolumab plus cabozantinib.

Two subject matter experts discuss survival and response data from the CheckMate 9ER trial comparing combination nivolumab/cabozantinib to sunitinib in patients with advanced ccRCC.

Drs Choueiri and Gosain review study design, patient demographics, and clinical characteristics from the CheckMate 9ER trial, including prior nephrectomy and PD-L1 status.

Toni Choueiri, MD, and Rohit Gosain, MD share their clinical experience treating patients with clear cell renal cell carcinoma (ccRCC) and provide a short summary of previously reported data from the CheckMate 9ER trial.